Proton beam therapy potential

An overview of MCL from EHA 2016

The value and strategy for incorporating biosimilars Into clinical practice

Checkpoint inhibitor therapy benefits advanced bladder cancer patients

Neuroblastoma outcomes improved with second stem cell transplant

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer

Sequencing analysis with circulating DNA

Consolidative therapy extends PFS for NSCLC patients

Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

Cochlear sparing via intensity modulated radiotherapy

Ten years of letrozole improves survival and quality of life in early-diagnosed breast cancer.